Nitrates are a cornerstone in the treatment of coronary heart disease and heart failure.
Although they are widely used in clinical practice, their therapeutic value is partially compromised
by the rapid development of tolerance. The effect of different nitrates, nitroglycerin
(NTG), isosorbide dinitrate (ISDN), 5-mononitrate (5MN) and 2-mononitrate (2MN) and the mechanism
responsible for nitrate tolerance were investigated on isolated rabbit hearts and aortic
strips. Preparation was stimulated by different spasmogenic agents: KCl, angiotensin II (A) and
noradrenaline (NA); nitrates were administered on the plateau contraction, at the concentration
of maximum inhibitory effect. Nitrates produced the following maximum inhibitions on NA-induced
contraction: NTG 90% (10–6 M), ISDN 60% (10–4 M), 5MN 55% (10–4 M) and 2MN 80%
(10–4 M). In another series of experiments, preparations were pre-incubated with the maximum
inhibitory concentration of each nitrate to evaluate the induction of tolerance. After incubation a
loss of vasodilator effect of nearly 50-60% was observed for all the nitrates considered except
2MN, in which the loss of effect was significantly lower (36%). The cyclic GMP (cGMP) levels
measured in the preparations were lower in the presence of 2MN than in the other compounds.
These data suggest that 2MN is able to induce a lesser cGMP increase and a lesser tolerance induction;
since these observations seem to be correlated the vasodilator effect of 2MN probably involves
mechanisms other than guanylyl cyclase stimulation. (Heart International 2007; 3: 112-21)
Nitroglycerine, Tolerance induction, Nitric oxide, Isosorbide mononitrate
Prof. Riccardo Raddino, Section of Cardiovascular Diseases – Department of Applied, Experimental Medicine, University of Brescia, Operative Unit of Cardiology, “Spedali Civili” Hospital, Brescia – Italy, riccardo.raddino@libero.it

Trending Topic
Hypertension is the leading modifiable risk factor for global cardiovascular disease, responsible for an estimated 10.8 million deaths and more than 200 million disability-adjusted life years annually.1 Despite the availability of effective pharmacological and lifestyle interventions, prevalence continues to rise, particularly in low- and middle-income countries (LMICs), where over three-quarters of all cases now occur.2 The condition’s […]
Hypertension is the leading modifiable risk factor for global cardiovascular disease, responsible for an estimated 10.8 million deaths and more than 200 million disability-adjusted life years annually.1 Despite the availability of effective pharmacological and lifestyle interventions, prevalence continues to rise, particularly in ...
Hypertension affects over 1.4 billion adults worldwide and remains the leading modifiable risk factor for global cardiovascular (CV) morbidity and mortality. It is responsible for an estimated 10.8 million deaths annually and contributes significantly to the global burden of ischaemic heart disease, ...
Hypertension has been associated with increased cardiovascular morbidity and mortality, as well as with overall elevated all-cause mortality.1 Prevalence increases with age, affecting 28.5% of US individuals aged 20–44 years, 58.6% of those aged 45–64 years and 76.5% of those aged 65 years and older.2 In ...
Hypertension (HTN) is one of the largest contributors to cardiovascular (CV) morbidity and mortality in the USA and is estimated to affect 47% of the adult population or approximately 122 million adults older than 20 years of age.1 Recent estimates suggest that over 40% ...
Atrial fibrillation (AF) is one of the most common arrhythmias. It affected 33.5 million people worldwide in 2010, a number that is expected to double by 2050.1 AF prevalence increases with age, and approximately 25% of individuals aged 40 years or older will develop AF ...
Hypertension is a global health problem, with an estimated 1.13 billion individuals affected.1 Patients with hypertension, especially when resistant to conventional therapy, are at high risk of sequelae, e.g., ischaemic heart disease, haemorrhagic and ischaemic stroke, cardiac failure, peripheral vascular ...
Keep track of your clinical interests and newsletter subscriptions.
Register for free to hear about the latest expert-led education, peer-reviewed articles, conference highlights, and innovative CME activities.
Or use a Social Account.
Already registered? Login below.